SCHEMBL6479697

SCHEMBL6479697

CCOC(=O)/C=C/c1ccc(O)c(-c2cc3c(cc2OCc2ccc(F)cc2)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.50
TTR P02766 2/20 0.46
DPP4 P27487 1/20 0.46
MAOB P27338 1/20 0.45
CA12 O43570 4/20 0.42
CA7 P43166 4/20 0.42
CA9 Q16790 4/20 0.42
CA14 Q9ULX7 4/20 0.42
CA4 P22748 3/20 0.42
CA6 P23280 3/20 0.42
CA5A P35218 3/20 0.42
CA5B Q9Y2D0 3/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 1/20 0.41
AKR1B10 O60218 1/20 0.41
AKR1B1 P15121 1/20 0.41
CYP3A4 P08684 1/20 0.40
AKR1C3 P42330 2/20 0.40
FDPS P14324 1/20 0.40
MET P08581 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479699 1.00 RXRA (0.50) RXRATTRDPP4MAOBCA12
SCHEMBL6479475 0.92 RXRA (0.55) RXRATTRDPP4MAOBCA12
SCHEMBL6479478 0.92 RXRA (0.55) RXRATTRDPP4MAOBCA12
SCHEMBL6473217 0.91 RXRA (0.50) RXRATTRDPP4MAOBCA12
SCHEMBL6473219 0.91 RXRA (0.50) RXRATTRDPP4MAOBCA12
SCHEMBL6479230 0.91 RXRA (0.50) RXRATTRDPP4MAOBCA12
SCHEMBL6479229 0.91 RXRA (0.50) RXRATTRDPP4MAOBCA12
SCHEMBL6472504 0.89 RXRA (0.61) RXRACA9CA5ACA2AKR1C3
SCHEMBL6472506 0.89 RXRA (0.61) RXRACA9CA5ACA2AKR1C3
SCHEMBL6472798 0.86 RXRA (0.48) RXRATTRDPP4MAOBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R RXRA 174/4885TTR 1262/4885DPP4 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.